ArticleTranslational cancer research2026
LINC01614 favors breast cancer progression through the regulation of miR-217/FN1 and mediation in PI3K/AKT signal pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most prevalent malignant tumor and represents a significant threat to women's health. Long non-coding RNAs (LncRNAs), which are RNA molecules longer than 200 nucleotides, have been shown to play critical roles in the progression of BC. Therefore, this study was aimed to explore the function and potential mechanism of LINC01614 in BC, so that it could provide new strategies for future BC therapy. Methods: This study used the TANRIC and ENCORI databases to evaluate LINC01614 expression and its prognostic significance. Cell Counting Kit-8 (CCK-8), wound healing, Transwell, and apoptosis assays were conducted to assess its biological function in BC cells. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot (WB) were employed to explore the molecular mechanisms involved. Enzyme-linked immunosorbent assay (ELISA) detection and in vivo experiments further clarified its role in BC. Results: The expression of LINC01614 was significantly elevated in BC and correlated with poor prognosis. Elevated LINC01614 expression enhanced BC cell proliferation, migration, and invasion, whereas its knockdown decreased cell viability, inhibited migration and invasion, and triggered apoptosis. Gene expression analysis after LINC01614 knockdown revealed changes in miR-217, FN1, PI3K, AKT, and PTEN levels. Additionally, co-silencing LINC01614 and miR-217 significantly affected PI3K, AKT, PTEN, and FN1 expression. Luciferase assays confirmed direct regulatory interactions between LINC01614 and miR-217, as well as between miR-217 and FN1. Metabolic analysis indicated that LINC01614 knockdown enhanced cellular energy metabolism. Conclusions: These results indicate that LINC01614 facilitates BC progression by regulating the PI3K/AKT signaling pathway through miR-217/FN1. Targeting LINC01614 may provide new therapeutic strategies for BC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.